Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

iMCI leads $1.25 million investment in Tulsa-based MS Pen Technologies, Inc.

By katelynn | Uncategorized | Comments are Closed | 14 July, 2020 | 0

Genio Technologies, Inc. has acquired exclusive rights to the MasSpec Pen System, a revolutionary technology from the University of Texas at Austin that is proven to accurately identify the difference between cancerous and normal tissue during surgery.

The MasSpec Pen System, developed in the lab of Livia Schiavinato Eberlin, Ph.D., is composed of a handheld and biocompatible pen-like device connected to a mass spectrometer that rapidly identifies the molecular profile of tissues during surgery. The technology will fill a current need in medicine by diagnosing cancer more quickly and more accurately than current methods and procedures. The MasSpec Pen will enable surgeons to operate more accurately and confidently, ultimately saving valuable time and money while improving patient outcomes.  

In November 2019, i2E Management Company, Inc. led a $1.25 million seed-round investment in Tulsa-based MS Pen Technologies, Inc. to advance and commercialize the MasSpec Pen System. The investment round included funds from the Oklahoma Seed Capital Fund and private investors.

“We will use the proceeds from the seed round to finalize our regulatory and compliance strategy, improve manufacturing readiness and continue ongoing surgical pilot studies,” CEO Shannon Green said upon closing the round.

About i2E and iMCI
i2E Management Company, Inc. (iMCI) is a private, for profit investment and fund management company operating as a wholly owned subsidiary of i2E, Inc. iMCI currently manages $88 million across five venture funds. iMCI makes investment decisions and provides investment management as General Partner and/or Managing Member of a growing number of privately managed venture capital funds. Since 2007, iMCI and i2E, Inc. have invested more than $58 million into 56 companies representing seed-stage to early-stage venture capital investments across many different industries including the life sciences and software/IT.

diagnosing cancer more quickly, Genio Technologies, handheld and biocompatible pen-like device, i2E, i2E Management Company, Inc., Livia Schiavinato Eberlin, mass spectrometer, MasSpec Pen System, MS Pen Technologies, Oklahoma Seed Capital Fund, Shannon Green, University of Texas at Austin

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

618 E. Third Street, Suite 1
Tulsa, OK 74120
PHONE 918/582-5592
Click HERE for printable map with directions.
Copyright 2021 i2E, Inc. | All Rights Reserved
  • #withOklahomaStartups
  • #withOklahomaStartups
  • #withOklahomaStartups- copy
  • 2016 BrewFest
  • 2018 Paulsen Award Application
  • 2019 Business Plan Submittal Form
  • 2019 Intent to Compete
  • 2019 Oral Competition Submittal Form
  • 2019 Paulsen Award Application
  • 2020 Business Plan Submittal Form
  • 2020 Oral Competition Submittal Form
  • 2020 Paulsen Award Application
  • 2021 Official Application Form
  • 2021 Oral Competition Submittal Form
  • 2021 Paulsen Award Application
  • 4DSales
  • About
  • About i2E
  • About Us
  • ACT Tulsa
  • Add Listing
  • Alkami
  • Biolytx
  • BP Endo
  • Clear River Enviro
  • Concept Fund
  • Contact
  • COVID-19 News from i2E
  • COVID19 Resources for Scalable Startups
  • CreditPoint
  • Datebox
  • DermaMedics
  • DEX Pump
  • DigitalSix
  • Directory
  • Directory Dashboard
  • Docvia
  • Driven Analytics
  • e3
  • e3 Goes Virtual
  • e3: #withOklahomaStartups
  • Entrepreneurial Development
  • Entrepreneurial Summit
  • Entrepreneurial Summit Speakers
  • Entrepreneurs-in-Residence
  • Entrepreneurship
  • Events
  • Events
  • Exaptive
  • Exerbotics
  • Expert TA
  • Founder’s Book Nook
  • Home
  • Home
  • i2E Directory
  • i2E Events
  • iMCI
  • iMCI Investment Funds
  • Investments
  • iRecommend
  • Kirrhos
  • Letter from iMCI’s Executive in Residence in a time of great uncertainty
  • Library
  • Lifetone
  • Linear Health Sciences
  • Love’s Cup
    • Forms
    • High Growth
    • Paulsen Awards
    • Small Business
    • Timeline
  • Love’s Cup is Unstoppable
  • Love’s Cup W-9
  • MaxQ
  • Moleculera Labs
  • Monscierge
  • MS Pen Technologies
  • My Account
  • News
  • Newsletter
  • Newsletter Archive
  • OKBio
  • OKBio Directory
  • OMRF Glioblastoma
  • Otologics Pharmaceuticals
  • Past Winners
  • PhotoniCare
  • PolySkope Labs
  • Portfolio
  • Portfolio 3
  • Private Partners Opportunity Fund
  • Progentec Diagnostics
  • Q&A with Kevin Moore
  • Q&A with Michael Basch
  • Quarterly Report
  • Raw Space for Rent
  • Resources
  • Roll to Roll Technologies
  • Selexys Pharmaceuticals
  • Send a Ride
  • Simergent
  • Spiers New Technologies
  • Synercon Technologies
  • Tailwind
  • Ten Nine Technologies
  • Testimonials
  • Tetherex Pharmaceuticals
  • The Greg Main Distinguished Scholar Award
  • THG Energy Solutions
  • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
  • Thoughts Post Shut In
  • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
  • Tulsa GEW
  • Valve Systems International
  • Venture Advisory Services
  • Video
  • Virtuoso
  • Webmail Test Page
  • WeGoLook
  • Well Checked Systems
  • Whiteboard CRM
i2E